Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
(University of Texas M. D. Anderson Cancer Center) According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2020 Category: Cancer & Oncology Source Type: news

Phase I Trial Aims to Evaluate Cobomarsen in Certain Hematologic Malignancies
The phase I trial is evaluating cobomarsen in cancers where the disease process appears to be correlated with an increase in miR-155 levels, including adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 4, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA clears investigational new drug application for Calibr's 'switchable' CAR-T therapy
(Scripps Research Institute) Calibr, the drug discovery and development division of Scripps Research, today announced that the US Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's 'switchable' CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 3, 2020 Category: International Medicine & Public Health Source Type: news

AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with a fixed duration for patients with previously untreated chronic lymphocytic leukemia (CLL) Represents thir... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 31, 2020 Category: Pharmaceuticals Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product ...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news

Single-cell sequencing of CLL therapy: Shared genetic program, patient-specific execution
(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Researchers at the CeMM Research Center for Molecular Medicine and partners in Budapest have studied the response to targeted leukemia therapy in unprecedented detail, using single-cell sequencing and epigenetic analysis. The paper published in Nature Communications uncovers a precise molecular program in patients with chronic lymphocytic leukemia (CLL) who start treatment with ibrutinib. While this program was shared by all patients, the speed of its execution differed widely. These results will help develop personalized strategies for manag...
Source: EurekAlert! - Cancer - January 29, 2020 Category: Cancer & Oncology Source Type: news

Idelalisib May Induce More Favorable Outcomes in Clinical Trial Participants, Versus Medicare Beneficiaries
Medicare beneficiaries saw unfavorable results when compared to clinical trial participants being treated with idelalisib for their follicular lymphoma or chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - January 17, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Jennifer A. Woyach, MD, on the Alliance A041702 Trial in Chronic Lymphocytic Leukemia
The Ohio State University Comprehensive Cancer Center expert discussed the ongoing Alliance A041702 trial at the ASH Annual Meeting and Exposition. (Source: CancerNetwork)
Source: CancerNetwork - January 2, 2020 Category: Cancer & Oncology Authors: Jennifer A. Woyach, MD Source Type: news

CLL Highlights From ASH 2019 CLL Highlights From ASH 2019
Dr William Wierda of MD Anderson Cancer Center reviews key studies on chronic lymphocytic leukemia therapies presented at the 2019 American Society of Hematology (ASH) meeting in Orlando, Florida.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

Revolutionary two-pronged attack that's beating 'incurable' blood cancer 
Professor Lelia Duley, 61, from Southwell in Nottinghamshire, is one of the patients involved in a drug combination trial to combat chronic lymphocytic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - December 28, 2019 Category: Consumer Health News Source Type: news

A 66-Year-Old Man With Leukemia: USMLE Question A 66-Year-Old Man With Leukemia: USMLE Question
A 66-year-old man is found to have chronic myelogenous leukemia after a routine office visit. What is the most appropriate initial treatment in this case?Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2019 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news

Survival Up for Chronic Lymphocytic Leukemia 1995 to 2017
THURSDAY, Dec. 26, 2019 -- For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia& Lymphoma. Rudolf Weide, M.D., from the Praxis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 26, 2019 Category: Pharmaceuticals Source Type: news

Cancer Drug Nilotinib Shows Promise for Parkinson's Patients
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson's disease, a new study finds. In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 16, 2019 Category: General Medicine Source Type: news

Cancer Drug Shows Promise for Parkinson's Patients
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson's disease, a new study finds. In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 16, 2019 Category: General Medicine Source Type: news

Chronic leukaemia drug breakthrough could cut side effects
Scientists at the South Australian Health and Medical Research Institute tested a drug on 150 cancer patients and said it was better tolerated than alternatives because it didn't attack healthy cells. (Source: the Mail online | Health)
Source: the Mail online | Health - December 11, 2019 Category: Consumer Health News Source Type: news

IMBRUVICA ® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
· Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were m aintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)· Integrated analysis from RESONATETM and RESONATETM-2 studies in CLL (Abstract #3054) reported long-term PFS, OS and response rates with earlier treatment with IMBRUVICA® · IMBRUVICA® plus ven e...
Source: Johnson and Johnson - December 9, 2019 Category: Pharmaceuticals Source Type: news

Merck drops $2.7B on 26-year-old Burlington biotech
Drug giant Merck& Co. announced Monday that it will spend billions to buy a 26-year old biotech company that's struggled to bring a cancer drug to market.   Merck (NYSE: MRK) will spend approximately $2.7 billion to acquire Burlington-based ArQule Inc. (Nasdaq: ARQL). The biotech's drug that's furthest along in clinical trials is in the mid-stage tests against relapsed or refractory chronic lymphocytic leukemia. ArQule is expected to disclose more clinical data at an industry conference Monday. ArQule,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 9, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Ibrutinib/Rituximab Combo Induced Superior PFS in Older Patients with CLL
The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news

Frontline Triplet Regimen Induces Undetectable MRD in the Bone Marrow of Patients with CLL
The triplet regimen consisting of acalabrutinib, venetoclax, and obinutuzumab appeared highly active as frontline therapy for patients with chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news

New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data from two pivotal phase III Venclexta ®/Venclyxto® (venetoclax) studies (MURANO and CLL14) that highlight Venclexta/Venclyxto combination treatments as chemotherapy-free, fixed-duration options that achieve minimal residual disease (MRD)-negativity, in people with chronic lymphocytic leukaemia (CLL). (Source: Roche Media News)
Source: Roche Media News - December 8, 2019 Category: Pharmaceuticals Source Type: news

New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data from two pivotal phase III Venclexta ®/Venclyxto® (venetoclax) studies (MURANO and CLL14) that highlight Venclexta/Venclyxto combination treatments as chemotherapy-free, fixed-duration options that achieve minimal residual disease (MRD)-negativity, in people with chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - December 8, 2019 Category: Pharmaceuticals Source Type: news

Frontline Ibrutinib/Venetoclax Provides High Rates of Undetectable MRD in CLL
First-line treatment with ibrutinib plus venetoclax provided high rates of undetectable minimal residual disease in peripheral blood and bone marrow of patients with chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

Acalabrutinib Regimens Improve PFS in Treatment-Na ïve Patients with CLL
Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-na ïve patients with chronic lymphocytic leukemia (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients
(ECOG-ACRIN Cancer Research Group) The ECOG-ACRIN Cancer Research Group today announced results from extended follow-up of patients in its randomized Phase 3 clinical trial, E1912. Previously untreated patients (aged 70 or younger) with chronic lymphocytic leukemia (CLL) who received ibrutinib-based therapy lived longer and with sustained benefit, compared to standard FCR chemoimmunotherapy. The updated analysis supports the earlier trial findings (Shanafelt, New England Journal of Medicine, August 2019). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2019 Category: International Medicine & Public Health Source Type: news

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Though safe, nilotinib does not show promise for benefit for Parkinson's disease
(Northwestern University) The Nilotinib in Parkinson's Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for potential repurposing as a Parkinson's drug, was safe and tolerable in its trial population of 76 participants with moderate to advanced Parkinson's but does not exert a clinically meaningful benefit or biological effect to benefit those with Parkinson's disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2019 Category: International Medicine & Public Health Source Type: news

Calquence Approved to Treat CLL, SLL
FRIDAY, Nov. 22, 2019 -- The U.S. Food and Drug Administration has granted supplemental approval to Calquence (acalabrutinib) for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the agency announced... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 22, 2019 Category: General Medicine Source Type: news

Ohio State-developed drug receives FDA approval for treatment of CLL and SML
(Ohio State University Wexner Medical Center) On Nov. 21, 2019, the US Food and Drug Administration (FDA) approved the use of the drug acalabrutinib for first-line therapy in chronic lymphocytic leukemia and small cell lymphoma. This is the first full approval of the targeted drug therapy, which was developed and tested at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, in collaboration with the pharmaceutical partner, Acerta Pharma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2019 Category: Cancer & Oncology Source Type: news

AstraZeneca gets FDA ok for lymphocytic leukemia drug
AstraZeneca announced that the U.S. FDA has approved Calquence for adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 21, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
21 November 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 The... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Acalabrutinib to Treat CLL/SLL
As part of Project Orbis, The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 21, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or younger RARITAN, N.J., Nov. 8, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharma... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2019 Category: Pharmaceuticals Source Type: news

UCLA Health partners with Kareem Abdul-Jabbar on health and wellness
UCLA legend and NBA Hall of Famer Kareem Abdul-Jabbar is teaming up with UCLA Health for a wide variety of new health and wellness initiatives designed to improve health and prevent disease.The partnership will be announced at the 2019 Leukemia and Lymphoma Society ’s Los Angeles Light the Night Walk, an event for which UCLA Health is the presenting sponsor.  The Los Angeles Laker superstar and UCLA Bruin basketball player is a survivor of chronic myeloid leukemia, or CML, which is a form of blood cancer. To honor his survivorship, Abdul-Jabbar has served as an ambassador and UCLA Health fundraising team ca...
Source: UCLA Newsroom: Health Sciences - November 7, 2019 Category: Universities & Medical Training Source Type: news

Risk for Second Primary Malignancy Up in CLL Survivors
FRIDAY, Nov. 1, 2019 -- Survivors of chronic lymphocytic leukemia (CLL) have an increased risk for second primary malignancy (SPM), according to a study published online Sept. 30 in Blood Cancer Journal. Vivek Kumar, M.D., from Harvard Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2019 Category: Pharmaceuticals Source Type: news

PHARMAC funding venetoclax for chronic lymphocytic leukaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2019 Category: Drugs & Pharmacology Source Type: news

Antibody eradicates leukemia stem cells
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80% of people with CML who received the drug, the disease went into complete remission.However, in most people with chronic myelogenous leukemia, cancerous stem cells remain in the body for years after their cancer has gone into remission. If treatment with imatinib or another similar medication is stopped — and in some cases, even while treatment continues — the leukemia stem cells can cause cancer to recur.Now, in experiments in mice as well as isolated human cancer ...
Source: UCLA Newsroom: Health Sciences - October 15, 2019 Category: Universities & Medical Training Source Type: news

Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Hypertension & CV Adverse Events With Ibrutinib in'Real World'Hypertension & CV Adverse Events With Ibrutinib in'Real World '
Ibrutinib has changed the treatment landscape of chronic lymphocytic leukemia, but emerging real-world data suggest caution, owing to hypertension and other CV adverse events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Blast Count Prognostic for CML Presenting in Advanced Phase
THURSDAY, Sept. 26, 2019 -- Blast count seems to be the main prognostic count for patients with chronic myeloid leukemia (CML) presenting in an advanced phase, according to a study published online Aug. 27 in the American Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 26, 2019 Category: Pharmaceuticals Source Type: news

Chronic Lymphocytic Leukemia: 5 Things to Know Chronic Lymphocytic Leukemia: 5 Things to Know
The most common adult leukemia has seen a rush of new evidence in recent years. Here are some of the highlights.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

Leukemia drug shows promise for treating a childhood brain cancer
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego. (Source: World Pharma News)
Source: World Pharma News - September 23, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 22, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Practical Dosing Considerations for Venetoclax
With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists.   (Source: CancerNetwork)
Source: CancerNetwork - September 20, 2019 Category: Cancer & Oncology Authors: Kelly Valla, PharmD, BCOP Source Type: news

Chronic Myeloid Leukemia: 5 Things to Know Chronic Myeloid Leukemia: 5 Things to Know
In the wake of the tyrosine kinase inhibitor revolution, where is the treatment of CML headed?Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

' Possibility of Cure' for Some Patients With CLL'Possibility of Cure' for Some Patients With CLL
Ibrutinib is rapidly changing the treatment landscape in chronic lymphocytic leukemia (CLL), and experts are now talking about the possibility of a cure for some patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Ibrutinib Combo in Chronic Lymphocytic Leukemia is Superior, but Costly
While  ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients. (Source: CancerNetwork)
Source: CancerNetwork - September 3, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Measurable Residual Disease Negativity at a High in Leukemia Trial
The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax. (Source: CancerNetwork)
Source: CancerNetwork - August 20, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Promising Blood Test Could Help to Predict Breast Cancer Recurrence
Doctors have gotten much better at detecting and treating breast cancer early. Drug and chemotherapy regimens to control tumors have gotten so effective, in fact, that in some cases, surgery is no longer necessary. In up to 30% of cases of early-stage breast cancer treated before surgery, doctors can’t find evidence of cancer cells in postoperative biopsies. The problem, however, is that there is currently no reliable way to tell which cancers have been pushed into remission and which ones have not. That’s where an easy identifier, like a blood test, could transform the way early stage breast cancer is treated....
Source: TIME: Health - August 8, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized blood tests Breast Cancer Source Type: news